Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Non-metastatic Colon Cancer
NCT02774512Phase 1Withdrawn
- Sponsor
- Institut Bergonié
- Start
- May 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nilotinib in colon cancer, sponsored by Institut Bergonié. Primary endpoint: ZAK expression level by immunohistochemistry and Western blot at Day 7. Planned start May 2016; status: withdrawn.
02
Drugs
nilotinib
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02774512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02774512.